Blog

Notes and updates

What the published literature reports on the compounds in this catalogue, and how to handle them once they arrive. Every figure is attributed to the trial it came from.

August 9, 2026
Retatrutide, Tirzepatide and Semaglutide: one receptor, two, or three
Semaglutide acts at one receptor, Tirzepatide at two, Retatrutide at three. Each addition was a bet about mechanism, and the published trials record what each bet returned — in separate trials that were, with one exception, never run against each other.
Read
August 9, 2026
Reconstitution, storage and concentration — handling lyophilised peptides in the lab
A dry peptide keeps; the same peptide in solution does not. Which water is which, how the solvent should meet the cake, what the concentration arithmetic actually is, and why a vial with no volume written on it has no known concentration.
Read
August 9, 2026
BPC-157 and TB-500 — what the recovery peptide literature actually contains
Neither compound has a controlled result in people, so this post publishes no figures at all — and the reason is the interesting part. BPC-157 has a large literature written almost entirely by one research group; TB-500 has a small one, and the human trials usually quoted for it belong to a different, longer molecule.
Read
August 9, 2026
CJC-1295 and Ipamorelin — two different ways to reach growth hormone
CJC-1295 and Ipamorelin are named together so often that the pairing reads as one subject, yet they reach growth hormone through different receptors and have been taken to very different stages in people. What the published studies measured, and the DAC distinction that most descriptions blur.
Read
August 9, 2026
Semax and Selank — peptides registered in one country and unstudied in most others
Both came out of the same Moscow institute, both are registered medicines in Russia, and neither holds a marketing authorisation in the European Union, the United Kingdom or the United States. What that evidential split does and does not let a reader conclude — and why no effect figure appears anywhere on this page.
Read
August 9, 2026
NAD+ and SS-31 — two routes to the mitochondrion, two very different evidence bases
Both are pitched at the mitochondrion, and there the resemblance ends. Almost every human figure quoted for NAD+ comes from a trial of an oral precursor, while SS-31 has a Phase 3 trial that missed both its primary endpoints — and that miss is the more informative result.
Read
August 9, 2026
How to read a certificate of analysis — what purity actually means on a peptide vial
A purity figure on a peptide certificate is a percentage of chromatogram area, not a statement about everything in the vial. What HPLC measures, what mass spectrometry measures instead, and the one check worth doing the moment a delivery arrives.
Read

Notes and updates

Retatrutide, Tirzepatide and Semaglutide: one receptor, two, or three

Reconstitution, storage and concentration — handling lyophilised peptides in the lab

BPC-157 and TB-500 — what the recovery peptide literature actually contains

CJC-1295 and Ipamorelin — two different ways to reach growth hormone

Semax and Selank — peptides registered in one country and unstudied in most others

NAD+ and SS-31 — two routes to the mitochondrion, two very different evidence bases

How to read a certificate of analysis — what purity actually means on a peptide vial